2026 Q1 -tulosraportti
71 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,54%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·24 min sittenMany interesting news for Novo lately! I am excited about the financial report on August 5th. Just uploaded an update about several of the latest news for Novo here: https://youtu.be/90P7rl6tQmQ
·25 min sittenAnalyst predicts: In these EU countries, the Wegovy pill will be launched first The launch of Novo Nordisk's Wegovy pill will begin in Denmark, Norway, Germany, and Spain. This is the assessment from senior analyst Søren Løntoft Hansen from AL Sydbank, writes news agency Direkt. Before the launch can commence, however, prices must be negotiated in the different countries. The analyst's statement comes the day after Novo Nordisk received approval to market the Wegovy pill in Europe.
1 t sittenFra Commerzbank til formiddag: Novo Nordisk has received EU approval for the oral Wegovy pill (25 mg) and the high-dose 7.2 mg injection pen. Wegovy is thus the first oral GLP-1 receptor agonist for the treatment of obesity in Europe, where the total GLP-1 market was valued at USD 14.27 billion in 2025 and is expected to reach USD 16.67 billion in 2026 (an increase of 16.8%). The approval is based on the OASIS-4 study, which showed a weight loss of 17% (vs. 3% with placebo). Novo Nordisk plans to launch the product in other European countries in the second half of 2026. Our assessment: The approval is a strategic milestone that opens up access to injection-averse patient groups. Since the decision was anticipated following the CHMP recommendation in May, the event is already priced into the current share price. Nevertheless, first-mover status in oral obesity therapies is of high strategic value for gaining market share early on. The critical operational risk remains securing capacity for the significantly higher drug demand of the oral formulation, while the new 7.2 mg pen safeguards the high-margin premium segment.
If Novo is quick with the logistics, they can get some weight-loss pills sold in Q4. Must be on everyone's Christmas gift list.- 1 t sittenNy analyse fra Handelsbanken: Ahead of Novo Nordisk's second quarter report, the focus remains on the development of the Wegovy tablet and the expansion in weight management. At the same time, the market's attention is increasingly turning to the company's growth prospects for 2027. Although the share has recovered significantly from the year's lows, we believe the valuation is still attractive. We therefore reiterate our Buy recommendation and raise the target price to DKK 365 (350). The share is currently trading at 15.0 times expected earnings over the next 12 months, compared to a ten-year average of 22.9 times. In addition, Novo Nordisk is now trading at only a 2 percent discount to global peers, compared to a 30 percent discount in February. Historically, the company has traded at a premium of around 42 percent. We reiterate our Buy recommendation and raise the target price to DKK 365 (350). The investment case continues to be based on two main factors: Our forecasts for the Wegovy tablet are above market consensus and market expectations continue to gradually rise. The volume potential from weight management treatments within Medicare Part D is likely greater than the market currently anticipates. Among the key risks, we see potential acquisitions of undifferentiated assets at high valuations.
A very credible and realistic analysis, which clearly appears from the price target of 365 and some in-depth analyses of the past and the industry in general. You can damn well see that it's written by independent professionals, unlike, for example, Jefferies, Zacks and Deutche Bank. 
·1 t sitten · MuokattuNice steady rhythm in the Novo share price, constantly building up👍 Not the 5-10 percent fluctuations, which are just professional traders sitting and stealing.
Are there any others than failed amateur speculators with hidden portfolios left on the formerly so-called "Shareville"? (smiles)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
71 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
3,54%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·24 min sittenMany interesting news for Novo lately! I am excited about the financial report on August 5th. Just uploaded an update about several of the latest news for Novo here: https://youtu.be/90P7rl6tQmQ
- ·25 min sittenAnalyst predicts: In these EU countries, the Wegovy pill will be launched first The launch of Novo Nordisk's Wegovy pill will begin in Denmark, Norway, Germany, and Spain. This is the assessment from senior analyst Søren Løntoft Hansen from AL Sydbank, writes news agency Direkt. Before the launch can commence, however, prices must be negotiated in the different countries. The analyst's statement comes the day after Novo Nordisk received approval to market the Wegovy pill in Europe.
- 1 t sittenFra Commerzbank til formiddag: Novo Nordisk has received EU approval for the oral Wegovy pill (25 mg) and the high-dose 7.2 mg injection pen. Wegovy is thus the first oral GLP-1 receptor agonist for the treatment of obesity in Europe, where the total GLP-1 market was valued at USD 14.27 billion in 2025 and is expected to reach USD 16.67 billion in 2026 (an increase of 16.8%). The approval is based on the OASIS-4 study, which showed a weight loss of 17% (vs. 3% with placebo). Novo Nordisk plans to launch the product in other European countries in the second half of 2026. Our assessment: The approval is a strategic milestone that opens up access to injection-averse patient groups. Since the decision was anticipated following the CHMP recommendation in May, the event is already priced into the current share price. Nevertheless, first-mover status in oral obesity therapies is of high strategic value for gaining market share early on. The critical operational risk remains securing capacity for the significantly higher drug demand of the oral formulation, while the new 7.2 mg pen safeguards the high-margin premium segment.If Novo is quick with the logistics, they can get some weight-loss pills sold in Q4. Must be on everyone's Christmas gift list.
- 1 t sittenNy analyse fra Handelsbanken: Ahead of Novo Nordisk's second quarter report, the focus remains on the development of the Wegovy tablet and the expansion in weight management. At the same time, the market's attention is increasingly turning to the company's growth prospects for 2027. Although the share has recovered significantly from the year's lows, we believe the valuation is still attractive. We therefore reiterate our Buy recommendation and raise the target price to DKK 365 (350). The share is currently trading at 15.0 times expected earnings over the next 12 months, compared to a ten-year average of 22.9 times. In addition, Novo Nordisk is now trading at only a 2 percent discount to global peers, compared to a 30 percent discount in February. Historically, the company has traded at a premium of around 42 percent. We reiterate our Buy recommendation and raise the target price to DKK 365 (350). The investment case continues to be based on two main factors: Our forecasts for the Wegovy tablet are above market consensus and market expectations continue to gradually rise. The volume potential from weight management treatments within Medicare Part D is likely greater than the market currently anticipates. Among the key risks, we see potential acquisitions of undifferentiated assets at high valuations.A very credible and realistic analysis, which clearly appears from the price target of 365 and some in-depth analyses of the past and the industry in general. You can damn well see that it's written by independent professionals, unlike, for example, Jefferies, Zacks and Deutche Bank.
- ·1 t sitten · MuokattuNice steady rhythm in the Novo share price, constantly building up👍 Not the 5-10 percent fluctuations, which are just professional traders sitting and stealing.Are there any others than failed amateur speculators with hidden portfolios left on the formerly so-called "Shareville"? (smiles)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
71 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
3,54%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·24 min sittenMany interesting news for Novo lately! I am excited about the financial report on August 5th. Just uploaded an update about several of the latest news for Novo here: https://youtu.be/90P7rl6tQmQ
- ·25 min sittenAnalyst predicts: In these EU countries, the Wegovy pill will be launched first The launch of Novo Nordisk's Wegovy pill will begin in Denmark, Norway, Germany, and Spain. This is the assessment from senior analyst Søren Løntoft Hansen from AL Sydbank, writes news agency Direkt. Before the launch can commence, however, prices must be negotiated in the different countries. The analyst's statement comes the day after Novo Nordisk received approval to market the Wegovy pill in Europe.
- 1 t sittenFra Commerzbank til formiddag: Novo Nordisk has received EU approval for the oral Wegovy pill (25 mg) and the high-dose 7.2 mg injection pen. Wegovy is thus the first oral GLP-1 receptor agonist for the treatment of obesity in Europe, where the total GLP-1 market was valued at USD 14.27 billion in 2025 and is expected to reach USD 16.67 billion in 2026 (an increase of 16.8%). The approval is based on the OASIS-4 study, which showed a weight loss of 17% (vs. 3% with placebo). Novo Nordisk plans to launch the product in other European countries in the second half of 2026. Our assessment: The approval is a strategic milestone that opens up access to injection-averse patient groups. Since the decision was anticipated following the CHMP recommendation in May, the event is already priced into the current share price. Nevertheless, first-mover status in oral obesity therapies is of high strategic value for gaining market share early on. The critical operational risk remains securing capacity for the significantly higher drug demand of the oral formulation, while the new 7.2 mg pen safeguards the high-margin premium segment.If Novo is quick with the logistics, they can get some weight-loss pills sold in Q4. Must be on everyone's Christmas gift list.
- 1 t sittenNy analyse fra Handelsbanken: Ahead of Novo Nordisk's second quarter report, the focus remains on the development of the Wegovy tablet and the expansion in weight management. At the same time, the market's attention is increasingly turning to the company's growth prospects for 2027. Although the share has recovered significantly from the year's lows, we believe the valuation is still attractive. We therefore reiterate our Buy recommendation and raise the target price to DKK 365 (350). The share is currently trading at 15.0 times expected earnings over the next 12 months, compared to a ten-year average of 22.9 times. In addition, Novo Nordisk is now trading at only a 2 percent discount to global peers, compared to a 30 percent discount in February. Historically, the company has traded at a premium of around 42 percent. We reiterate our Buy recommendation and raise the target price to DKK 365 (350). The investment case continues to be based on two main factors: Our forecasts for the Wegovy tablet are above market consensus and market expectations continue to gradually rise. The volume potential from weight management treatments within Medicare Part D is likely greater than the market currently anticipates. Among the key risks, we see potential acquisitions of undifferentiated assets at high valuations.A very credible and realistic analysis, which clearly appears from the price target of 365 and some in-depth analyses of the past and the industry in general. You can damn well see that it's written by independent professionals, unlike, for example, Jefferies, Zacks and Deutche Bank.
- ·1 t sitten · MuokattuNice steady rhythm in the Novo share price, constantly building up👍 Not the 5-10 percent fluctuations, which are just professional traders sitting and stealing.Are there any others than failed amateur speculators with hidden portfolios left on the formerly so-called "Shareville"? (smiles)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt